Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Regeneron ...

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Regeneron (REGN)

In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron, with a price target of $850.00. According to TipR...

Regeneron (REGN) Receives a Buy from BMO Capital

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Regeneron yesterday and set a price target of $745.00. According to TipRanks, Bansal i...

Wells Fargo Keeps Their Hold Rating on Regeneron (REGN)

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Regeneron, with a price target of $708.00. According to Tip...

RBC Capital Sticks to Its Hold Rating for Regeneron (REGN)

The Invesco QQQ ETF ($QQQ) rose 0.81% on Friday, with major indices ending the last trading session of November on a positive note. However, Novemb...

QQQ ETF Daily Update, 12/1/2025

Analysts are intrested in these 5 stocks: ( ($EXAS) ), ( ($REGN) ), ( ($MRVL) ), ( ($FROG) ) and ( ($JAZZ) ). Here is a breakdown of their recent


Exact Sciences, Regeneron, Marvell, JFrog, Jazz: Trending by Analysts

The Invesco QQQ ETF ($QQQ) rose 0.88% on Wednesday as major averages closed higher for the fourth straight day, ahead of the Thanksgiving holiday. ...

QQQ ETF News, 11/27/2025

Scotiabank analyst Louise Chen maintained a Hold rating on Regeneron today and set a price target of $770.00. Chen covers the Healthcare sector, fo...

Scotiabank Reaffirms Their Hold Rating on Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), Gilead Sciences ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them this month. These decisio...

Market Cap	$61.26B	P/E Ratio	21.23
52W High	$790.98	52W Low	$476.49
Div Yield	352.0%	Payout Ratio	18.3%
EPS Growth 3Y	-18.8%	52W Position	84.2%
Overall Score	75	Value Score	80
Quality Score	55	Technical Score	91

EPS Current Est	$34.92	EPS Next Est	$33.4
EPS Growth Est	-4.4%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$741.29	-0.74%	804.82K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$741.29	-0.7%	804.82K
3
4
5
6

REGN

REGN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Regeneron Pharmaceuticals Inc. Data in Excel

Get Regeneron Pharmaceuticals Inc. Data in Excel